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Comment  Ernst R. Berndt
Chapter 8 in this volume addresses a very important set of issues regarding 
implications of using retrospective medical claim transactions data to con-
struct price indexes for the treatment of episodes of various randomly cho-
sen medical conditions and diseases. Price index data initially collected by 
the Bureau of Labor Statistics (BLS) in Boston, New York City, and Phila-
delphia for use in its medical Consumer Price Index (CPI) are compared with 
medical claims data in the Thomson Reuters MarketScan Research Data-
bases, the latter based on transactions with providers/  retailers in the same 
three cities, all over the January 1999 to December 2002 time period. That 
the BLS commission this type of experimental study was recommended by 
the panel convened by the Committee on National Statistics.1 This chap-
ter represents the ﬁ  rst empirical evidence on the feasibility of constructing 
disease treatment-  based price indexes that allow for substitutability among 
medical inputs and on comparisons of their price trends with those pub-
lished by the BLS in its medical CPI.2
The authors construct a number of alternative price indexes, based on forty 
conditions randomly selected using expenditure versus population weights 
(the latter a simple count of the number of episodes treated), small samples 
(the same size as those used by the BLS in collecting data for the CPI), and 
large samples (about ten times the BLS sample size). Using medical CPI 
standard error data provided by the BLS and standard error estimates for 
the episode-  based price indexes obtained by implementing bootstrapping 
procedures, the authors then test whether any of the cumulative forty- eight-
  month price trends are statistically signiﬁ  cantly diﬀerent.
The central ﬁ  nding reported is that for the most part, while there appear 
to be very diﬀerent trends among cities and methods over shorter time peri-
ods, after forty-  eight months, the cumulative estimated price changes for 
the various methods are typically not statistically signiﬁ  cantly diﬀerent. In 
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1. Schultze, C., and C. Mackie, eds. 2002. At what price? Conceptualizing and measuring cost-
  of-  living and price indexes. Washington, DC: National Academies Press.
2. I note in passing that the version of the paper given at the Vancouver conference had 
a slightly diﬀerent title and contained considerably diﬀerent material than was in the initial 
revised version from late 2006. The version I comment on here is dated July 1, 2007, and it 
already incorporates responses to some of my comments made in 2006. The Vancouver ver-
sion was a draft by Xue Song, William D. Marder, Onur Baser, Robert Houchens, Jonathan E. 
Conclin, and Ralph Bradley, entitled “Can Health Care Claims Data Improve the Estimation 
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general and with several exceptions, while point estimates of the disease-
  based price indexes tend to suggest smaller price index growth after forty-
  eight months than does the medical CPI for each of the three cities, the 
boostrap-  based estimated standard errors are very large, resulting in the 
inability to reject the null hypothesis of no diﬀerence between them at usual 
p- values. Speciﬁ  cally, as reported in table 8.4, while the BLS all- medical- item 
CPIs have cumulative increases of 38 percent in Philadelphia, 23 percent 
in Boston, and 7 percent in New York City, the expenditure-  based disease 
indexes all have negative cumulative price changes: –  4 percent in Philadel-
phia, –  8 percent in Boston, and –  10 percent in New York City. Although 
the diﬀerences between the two are extremely large, being –  42 percent for 
Philadelphia, –  31 percent for Boston, and –  17 percent for New York City, 
only that for Boston (which has the largest claims sample size) is statistically 
signiﬁ  cantly diﬀerent from zero.
What is one to make of this initial evidence? I am reminded of my ﬁ  rst 
statistics course professor, who exhorted us students never to forget that ab-
sence of evidence is not the same as evidence of absence. I say this for several 
reasons.
First, relatively little information is given on how the bootstrap method 
was implemented and on the validity of the assumptions on which it is 
based. Speciﬁ  cally, it appears that the authors’ computation of bootstrap 
standard errors is based on the assumption of a random walk speciﬁ  cation, 
which is well-  known to generate nonstationarity. It would have been use-
ful for the authors to test for nonstationarity using available unit root tests 
and to assess the robustness of their estimated bootstrap standard errors 
under alternative speciﬁ  cations, such as stationary ones around a trend. If 
the random walk hypothesis is empirically invalid, it likely results in exag-
gerated standard error estimates. Whether alternative speciﬁ  cations of the 
underlying stochastic processes would have resulted in suﬃciently smaller 
standard errors to change qualitatively the general ﬁ  ndings of no diﬀerence 
in cumulative price growth over time is of course unknown. Admittedly, the 
random walk hypothesis is commonly used in ﬁ  nancial analyses of stock 
market movements, but its applicability to health care price changes is un-
clear. Careful and detailed discussion of this bootstrap speciﬁ  cation and 
computational procedure would have been useful. While analysts of claims 
expenditure (not price) data have long noted that large outlier observations 
are a trademark in health care, the standard errors of price ratios reported 
here are cause for concern.
Second, the research initiative reported by the authors seems remarkably 
preliminary and incomplete. Why, for instance, is the statistical comparison 
undertaken only after forty-  eight months, and not, for example, at yearly 
intervals? How would results have looked if the sample set of diseases were 
ﬁ  xed for the four years, rather than being updated annually, or after every 
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ber of one year to January of the next year, when the basket of treatment 
inputs is updated for each disease? What would have been the consequences 
of smoothing the weights over that year end to the beginning of the next 
year time interval or of using some other overlapping methods? Why do 
the expenditure weights for inpatient, outpatient, and prescription drugs 
diﬀer so much in both the CPI and claims data across cities and between the 
CPI and claims data for the same cities? How important are the various 
implementation methods that increase churning in contributing to the rela-
tively large standard errors? If one formed a three-  city aggregate of both 
the CPI and the various disease- based measures, would the price trends have 
become statistically signiﬁ  cantly diﬀerent, due to smaller standard errors? 
Although regional variations are of interest, in typical policy discussions, we 
are most concerned about measuring medical inﬂ  ation at an aggregate rather 
than city-  speciﬁ  c level of aggregation. Unfortunately, these types of rather 
obvious questions are not addressed in detail by the authors, and thus the 
reader is left rather puzzled, with the study raising enormous issues about 
both the CPI and Thomson Reuters underlying databases. Admittedly, the 
authors suggest that in future research, it might be useful to implement a 
two-  stage disease selection method, ﬁ  rst by major body organ system and 
then within that (an eminently reasonable suggestion that should not have 
been that diﬃcult to carry out). In general, the analysis undertaken and 
reported in the chapter is spartan and truly preliminary.
A number of other issues deserve attention. First, while economic theory 
provides a strong rationale for using expenditure weights, what is the ratio-
nale for sampling based on population weights? The BLS and Bureau of 
Economic Analysis do not generally publish democratic weights (expendi-
ture weights underlie plutocratic weighting schemes), so why even consider 
them here? Given the skewness of health care spending, one should expect 
substantial diﬀerences between expenditure-  and population- weighted price 
indexes, and that is exactly what is reported. Why not instead devote more 
resources to a deeper analysis of the expenditure-  weighted indexes? In any 
case, the expenditure-  based and population-  based indexes often display 
opposite trends for which no explanation is given.
Second, the careful reader will note from tables 8.1 and 8.2 that for the 
BLS medical CPI, in both Philadelphia (even-  numbered months) and 
Boston (odd-  numbered months), but not in New York City, the BLS only 
samples bimonthly. This creates a number of statistical complications when 
comparing their cumulative growth to all monthly disease-  based measures 
and raises the issue of why the periodicity for the disease-  based measures 
for Philadelphia and Boston diﬀer from those of the BLS for those cities. 
A related puzzling result in table 8.3 is, why is it that the expenditure-  based 
price index for prescription drugs goes up by 97 percent in Philadelphia and 
by 10 percent in Boston but drops by 39 percent in New York City? This 
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Third, because the transaction claims data represent the total payment to 
the provider (consumers’ out-  of-  pocket payments, plus third-  party payer’s 
payments to the provider), in some sense, the price index computed here bet-
ter resembles a producer price index by medical care providers than a CPI, 
particularly because the medical care CPI relies so very heavily on a real-
location of insurance premiums into insurance payouts and gross margins.3 
While the Producer Price Index scope is generally conﬁ  ned to domestically 
produced goods and services, whereas the CPI tracks price changes of goods 
and services, regardless of where they are produced, my understanding is 
that for health care goods and services, relatively few are produced abroad, 
and thus the claims-  based price index is more like a producer rather than 
consumer price index. A more complete discussion of these various issues 
would have been most useful.
Finally, a critical component of the analysis reported here involves the 
use of the Medstat Episode Grouper, which groups distinct medical claims 
over time into an episode of care, which in turn provides the basis for pricing 
inputs. The construction of such data into episode groupers involves com-
bining medical knowledge with insights from claims processors and statisti-
cians and reﬂ  ects a great deal of art. It is my understanding that there are a 
number of alternative episode groupers available commercially (and some 
in the public domain), and thus it would have been useful for the authors to 
devote some attention in the chapter to the existing literature that examines 
and compares the various episode groupers on criteria such as their internal 
and external validity.4
In summary, the topic addressed by this chapter is extremely important. 
That so little in-  depth analysis was undertaken, however, is disappointing. 
While the desirability of further research is typically mentioned in the con-
cluding section of empirical chapters, in this case, that need is truly great.
3. For further discussion, see Schultze and Mackie, 2002, At What Price?
4. A study by Ana Aizcorbe, Nicole Nestoriak, and others that compares price indexes from 
alternative episode groupers (including the Symmetry Episode Treatment Group product com-
mercially available from Ingenix, a subsidiary of United Health Care; available at http:/  /  www
.ingenix.com/  content/  File/  EvolutionofSymmetry.pdf) is currently underway. Initial ﬁ  ndings 
have been reported by Ana Aizcorbe and Nicole Nestoriak in a Powerpoint presentation at the 
Bureau of Economic Analysis Advisory Committee Meeting, entitled “Episode-  Based Price 
Indexes: Plans and Progress,” on May 4, 2007. Available at www.bea.gov.